Abstract
US prescription drug prices are substantially higher than other countries. Many states rely on price transparency policies to highlight discrepancies between the US and other markets to indirectly help cut pharmaceutical spending. Maine state legislation passed in April 2022 aims to compare US WAC prices of the 100 most costly and 100 most frequently prescribed drugs to the lowest list price in Canada (Ontario, Quebec, British Columbia, and Alberta). From January 2023, Maine Health Data Organization (MHDO) will begin annually reporting potential savings if these drugs were subject to the Canadian reference price.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
